journals

NEJM is the most influential medical journal. When a cancer drug trial changes how patients are treated, the paper is usually here, often published the same day it is presented at ASCO, ESMO or ASH.

The Lancet is Britain's leading general medical journal and the other main home of practice-changing cancer trials, with a stronger global-health and policy voice than NEJM.

The Journal of Clinical Oncology is ASCO's flagship journal and the workhorse of clinical oncology, publishing trials, ASCO guidelines, and the abstract supplements for the ASCO Annual Meeting.

The Journal of Nuclear Medicine is the SNMMI's journal and the core venue for PET tracers and radioligand therapy: PSMA and somatostatin imaging, lutetium and actinium dosimetry, and theranostics trials.

The Lancet Oncology is the leading specialist cancer journal for clinical trials. It publishes phase 2 and 3 trials, long-term follow-up, quality-of-life analyses and global-oncology policy Commissions.

A long-running European medical journal that publishes new research on radioactive scans and radioactive treatments.

The English-language journal of Japan's nuclear medicine society.

Annals of Oncology is ESMO's flagship journal, publishing European phase 3 trials, the ESMO Clinical Practice Guidelines and the abstract books for the ESMO Congress.

Cancer Biotherapy and Radiopharmaceuticals covers immunotherapy, targeted biological agents and radiolabelled drugs for cancer imaging and treatment, read by nuclear medicine and biotherapy researchers.

Cancer Imaging is the open-access journal of the International Cancer Imaging Society, covering CT, MRI, PET and other imaging of cancer. Read by radiologists and nuclear medicine specialists working in oncology.

China's main nuclear medicine journal. It publishes in Chinese, which is why most of its content is invisible to the usual English-language trackers.

AACR's clinical journal: phase 1 dose-escalation trials, biomarker studies, pharmacodynamics and the FDA approval summaries written by agency reviewers.

A monthly US medical journal for doctors who use radioactive scans and treatments in everyday patient care.

A specialist journal, launched in 2015, for the chemistry of making new radioactive imaging and therapy drugs.

European Urology is the European Association of Urology's journal and the most cited urology title, publishing prostate, bladder and kidney cancer trials, the EAU guidelines and PSMA imaging studies.

JAMA is the American Medical Association's flagship journal. It is strong on cancer screening, prevention, health-services and patient-reported-outcome research, and on the USPSTF recommendations.

The journal of the Australian and New Zealand college for radiologists and radiation oncologists, covering diagnostic imaging, nuclear medicine and radiotherapy. Read by radiologists and radiation oncologists in Australasia and beyond.

The official journal of the American nuclear cardiology society, covering heart scans that use radioactive tracers.

Nature Medicine is Nature's clinical journal and now a top venue for early-phase and biomarker-rich cancer trials, medical AI studies and cell-therapy reports.

A scientific journal for the chemistry side of radioactive drugs: how they are made, tested in cells and animals, and first tried in patients.

The English-language journal of Korea's nuclear medicine society.

Radiology is the RSNA's flagship journal, publishing imaging research including cancer screening performance, AI image analysis and response assessment.

Science Translational Medicine is AAAS's translational journal, publishing the bench-to-bedside cancer papers on liquid biopsy, CAR-T engineering, tumour-immune biology and new imaging agents.

A fully free-to-read journal that publishes research combining diagnosis and treatment, including radioactive drugs.